BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 223 filers reported holding BRIDGEBIO PHARMA INC in Q1 2023. The put-call ratio across all filers is 0.72 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $896,200 | -82.4% | 35,381 | -71.9% | 0.01% | -82.4% |
| Q4 2023 | $5,084,157 | +15.4% | 125,939 | -24.6% | 0.03% | 0.0% |
| Q3 2023 | $4,406,928 | +1330.6% | 167,119 | +799.5% | 0.03% | +1033.3% |
| Q1 2023 | $308,039 | -68.2% | 18,579 | -80.9% | 0.00% | -62.5% |
| Q3 2022 | $970,000 | -39.7% | 97,519 | -44.9% | 0.01% | -50.0% |
| Q2 2022 | $1,608,000 | -26.7% | 177,026 | -18.2% | 0.02% | -20.0% |
| Q1 2022 | $2,195,000 | -19.2% | 216,300 | +32.8% | 0.02% | -20.0% |
| Q4 2021 | $2,717,000 | +218.5% | 162,900 | +795.1% | 0.02% | +177.8% |
| Q3 2021 | $853,000 | -70.2% | 18,200 | -61.2% | 0.01% | -70.0% |
| Q2 2021 | $2,858,000 | +2.8% | 46,887 | +3.9% | 0.03% | -11.8% |
| Q1 2021 | $2,780,000 | +337.8% | 45,137 | +405.7% | 0.03% | +277.8% |
| Q4 2020 | $635,000 | -28.7% | 8,926 | -62.4% | 0.01% | -47.1% |
| Q3 2020 | $890,000 | +2.1% | 23,741 | -11.1% | 0.02% | +41.7% |
| Q2 2020 | $872,000 | – | 26,692 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 6,068,125 | $60,317,000 | 40.05% |
| Kohlberg Kravis Roberts & Co. L.P. | 31,060,971 | $308,746,000 | 6.20% |
| M28 Capital Management LP | 513,300 | $5,102,000 | 5.33% |
| GREAT POINT PARTNERS LLC | 1,050,000 | $10,437,000 | 2.51% |
| Octagon Capital Advisors LP | 933,743 | $9,281,000 | 1.60% |
| HHLR ADVISORS, LTD. | 5,362,014 | $53,298,000 | 1.40% |
| VIKING GLOBAL INVESTORS LP | 26,620,991 | $264,613,000 | 1.22% |
| Cormorant Asset Management, LP | 1,469,179 | $14,604,000 | 1.02% |
| Fernwood Investment Management, LLC | 204,550 | $2,033,000 | 0.86% |
| TANG CAPITAL MANAGEMENT LLC | 585,424 | $5,819,000 | 0.71% |